In conclusion, the landscape of cancer immunotherapy response prediction is undergoing a transformative shift, with TLSs emerging as a compelling and potentially more robust biomarker compared with the extensively studied PD-L1 expression and TILs. This evidence concerns the gene CD274 and cancer.